Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
NT

NASDAQ · NTRB

Nutriband Inc.

Healthcare · Biotechnology

$5.76

Down-$0.05 (-0.86%)

Updated Oct 25, 2026, 4:01 AM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
56.14M
P/E ratio
-5.5
Dividend yield
0.00%
52-week range
$2.80 – $9.19
Volume
6.78K
Avg. volume
33.63K

Price performance · NTRB

NTRB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

NTRB closed at $5.76 after 20 trading sessions, down 30.01% for the selected period.

Last close
$5.76
Period change
-30.01%
Period low
$5.76
Period high
$8.25
Daily close
View OHLC price history
NTRB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$5.94$5.94$5.705$5.766.78K
Oct 22, 2026$6.2015$6.2015$5.81$5.8116.71K
Oct 21, 2026$5.85$6.23$5.80$6.1422.08K
Oct 20, 2026$5.9675$6.05$5.80$5.8516.68K
Oct 19, 2026$6.23$6.295$5.65$6.0079.24K
Oct 16, 2026$6.25$6.526$6.0001$6.2227.92K
Oct 15, 2026$6.30$6.799$6.25$6.2770.18K
Oct 14, 2026$6.50$6.6406$6.3026$6.3251.7K
Oct 13, 2026$5.89$6.80$5.89$6.5269.18K
Oct 12, 2026$6.57$6.57$5.85$5.8515.56K
Oct 9, 2026$6.00$6.82$5.70$6.6545.14K
Oct 8, 2026$6.75$6.75$6.03$6.0535.72K
Oct 7, 2026$6.58$7.0999$6.58$6.75510.22K
Oct 6, 2026$7.44$7.44$6.545$6.6887.02K
Oct 5, 2026$7.24$7.6499$7.23$7.4719.48K
Oct 2, 2026$7.46$7.8565$7.25$7.2847.05K
Oct 1, 2026$7.52$7.693$7.28$7.3642.17K
Sep 30, 2026$8.25$8.44$7.41$7.52147.74K
Sep 29, 2026$8.31$8.57$8.03$8.25140.53K
Sep 28, 2026$7.99$8.99$7.99$8.23284.82K

Latest NTRB news

The latest Smart Investors Daily articles mentioning NTRB.

Stock researchCompany · Overview

NTRB research

Overview

Company profile and research snapshot.

Company profile

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NTRB recent ratings
DateFirmRatingTarget
Jan 22, 2025Noble Capital MarketsOutperform—
Jul 26, 2022Small Cap Consumer ResearchBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 13, 2026

Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274

ORLANDO, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), announced today that it has seen 272,671 NTRBW warrants exercised at a strike price of $6.43 for proceeds to the company of $1,753,274.53. NTRBW warrants expired on September 30 with no extension. The Company has no remaining tradeable warrants. The primary use of proceeds will be used towards the remaining clinical development of AVERSA Fentanyl and submission of its NDA with the FDA for marketing approval. AVERSA Fe

Yahoo · Oct 8, 2026

Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology

Nutriband files new non-provisional patent application to strengthen intellectual property protection of its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. Nutriband’s AVERSA™ abuse-deterrent technology consists of a proprietary aversive agent coating that employs taste aversion to deter oral abuse and reduce accidental exposure. ORLANDO, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)

Yahoo · Oct 1, 2026

Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders

Nutriband CEO Gareth Sheridan Congratulates Shareholders on Five-Year Nasdaq Listing Anniversary CEO letter reflects on five years of milestones since the Company's October 1, 2021 uplisting, as AVERSA™ Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled ORLANDO, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) today announced that CEO Gareth Sheridan has published a letter to shareholders marking the fifth anniversary of the Company's l

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By